Characterization of a complex translocation [t(4;9;22)(p16;q34;q11)] in chronic myelogenous leukemia by fluorescence in situ hybridization technique

Cancer Genet Cytogenet. 1996 Sep;90(2):142-5. doi: 10.1016/s0165-4608(96)00095-7.

Abstract

A patient was referred with a high leukocyte count and diagnosed with chronic myelogenous leukemia (CML). Although practically asymptomatic since the time of diagnosis, he had a variable and inconsistent response to treatment. All of his bone marrow cells had a complex, three-way translocation, involving chromosomes 4, 9 and 22. Translocation of chromosome 4 to chromosome 9 was undetectable by routine cytogenetic techniques; however, by the fluorescence in situ hybridization technique, a three-way translocation was identified, 46,XY,t(4;9;22)(p16;q34;q11). Although, other chromosomes are frequently involved in complex or variant translocations with chromosome 9 and 22, participation of chromosome 4 is a very rare event. So far, two previous cases have been described in the literature with translocations involving chromosome 4p16. We present a third case of CML having similar break points whose clinical presentation is unusual.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Allopurinol / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Bone Marrow / pathology
  • Busulfan / therapeutic use
  • Chromosome Banding
  • Chromosome Mapping
  • Chromosomes, Human, Pair 22*
  • Chromosomes, Human, Pair 4*
  • Chromosomes, Human, Pair 9*
  • Humans
  • Hydroxyurea / therapeutic use
  • In Situ Hybridization, Fluorescence
  • Karyotyping
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Male
  • Middle Aged
  • Translocation, Genetic*

Substances

  • Antineoplastic Agents
  • Allopurinol
  • Busulfan
  • Hydroxyurea